Shamir Optical Industry Ltd. Reports Second Quarter 20... (ors research and development partners an...)

Shamir Optical Industry Ltd. Reports Second Quarter 2009 Results

Date:8/13/2009

ors, research and development partners and other third parties; the effects of the international expansion of our operations and our ability to manage our growth, including our ability to manage potential future acquisitions; the effect of global economic conditions in general and conditions in Shamir's industry and target markets in particular; shifts in supply and demand; market acceptance of new products and continuing products' demand; the impact of competitive products and pricing on Shamir's and its customers' products and markets; timely product and technology development/upgrades and the ability to manage changes in market conditions as needed; interest rate fluctuations; and other factors detailed in Shamir's filings with the Securities and Exchange Commission. Shamir assumes no obligation to update the information in this release.

    Investor Relations Contacts:
    Roni Gavrielov                   Jeffrey Goldberger/Marybeth Csaby
    KM / KCSA Investor Relations     KCSA Strategic Communications
    +972-3-516-7620                  212-896-1249/212-896-1236
    roni@km-ir.co.il                 jgoldberger@kcsa.com / mcsaby@kcsa.com

(Tables to follow)

SHAMIR OPTICAL INDUSTRY LTD.
Consolidated Balance Sheets
(US dollars in thousands,
except share and per share data)

As of December 31, As of June 30,
2008 2009
------------------ --------------
(Unaudited)

CURRENT ASSETS:
Cash and cash equivalents
'/>"/>
SOURCE Shamir Optical Industry Ltd.
Copyright©2009 PR Newswire.
All rights reserved
0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine news :

Post Your Comments:

(Date:11/25/2009)...zlesmile,llc www.dazzlesmile.com andOptimalHealthS...67-pagefederallawsuitagainstEpicAdvertisingAKAAzoo...esLimited,andAtLastFulfillment.The13-countComplain...ictofUtah,allegesmassivenationalconsumerfraud,coun...oducts,violationsoftheRacketeeringInfluencedandCor...

(Date:11/25/2009)...roveOverallOutcomesforLungCancer ,, WASHINGTO...rAlliance-California(LCA-CA)issuedits2ndAnnual Rep...ntofprogressbeingmadeagainstthislethaldiseaseinthe...ance(LCA),theonlynationalorganizationdedicatedexcl...ithoratriskforlungcancer. ,, (Photo: http://www...

(Date:11/25/2009)...matology (ASH) is pleased to recognize the followi...bstracts in the categories of undergraduate studen...ysician, and post-doctoral,fellow. Merit Award wi...g,travel reimbursement. , The 2009 Merit Award ...imberly Fan , Donor Dendritic Cells Home to Lymph...

(Date:11/25/2009)... , An innovative treatment for HIV patients dev...ers has passed its first clinical trial with flyin...stomized for each individual patient, and was deve...e of the MUHC in collaboration with Dr. R. Skaly f...ade for the individual patient an "haute couture"...

(Date:11/25/2009)...atients with liver lesions, researchers find , ...ding the drug cetuximab to neoadjuvant chemotherap...ul surgery in colorectal cancer patients with inop...ests. , , Tumors spread to other parts of the ... cancer. Most commonly, the cancer spreads to the ...

Breaking Medicine News(10 mins):Health News:dazzlesmile Sues Epic Advertising and Jesse Willms 2 Health News:Lung Cancer Alliance-California Releases 2nd Annual State-Specific Report Card On Lung Cancer 2 Health News:ASH announces 2009 Merit Award winners 2 Health News:Tailor-made HIV/AIDS treatment closer to reality 2 Health News:Cetuximab Helps Treat Colorectal Cancer 2

[0] dazzlesmile Sues Epic Advertising and Jesse Willms [0] Lung Cancer Alliance-California Releases 2nd Annual State-Specific Report Card On Lung Cancer [0] ASH announces 2009 Merit Award winners [0] Tailor-made HIV/AIDS treatment closer to reality [0] Cetuximab Helps Treat Colorectal Cancer

... due to its First To File ... Pharmaceuticals Inc.,(RPI), a wholly owned subsid...ed today that RLL has received tentative approval ...Valsartan Tablets,were $1.3 billion (IMS - MAT: Ju...

...onal, Inc. (OTC. Bulletin Board: TCAR.OB) today an...er 24, 2007, with The Hain Celestial,Group, Inc. (...d and personal,care products company. Under the te...1, 2006, there were 7,454,582 shares of,TenderCare...

...ated, doing business as "Merge Healthcare" (Nasdaq...ical imaging software and services provider,announ...ced restatement of,its financial statements, the C... 2005, and 2006, as well as other,restated financi...

...RUSSIA, Pa., Oct. 29 Universal,Health Services, I...d net,income was $28.9 million, or $.54 per dilute...red to $113.9 million, or $2.00 per diluted share,...hare, as compared to $225.3 million, or $3.89 per ...

... that,global prices for most of its soy protein in...ding on the product line. The increase takes effec... Chairman Craig Binetti said, "Market conditions a...provide innovative, economical solutions." For se...

...; RO.S),a world-leading healthcare provider of pha...it has extended its offer to acquire all of the,ou..., Inc. (Nasdaq: VMSI ),to 5:00 p.m., New York Cit...her terms and conditions of the tender offer,remai...

Ranbaxy Receives Tentative Approval For Valsartan Tablets TenderCare International, Inc. Announces Signing of Merger Agreement with the Hain Celestial Group for All Outstanding Shares of TenderCare Stock Merge Healthcare Provides Update on the Restatement of Its Financial Statements Universal Health Services, Inc. Reports 2007 Third Quarter Earnings Solae Announces Global Price Increase for Soy Protein Ingredients Roche Extends Tender Offer for Ventana

(Date:11/25/2009)....25/PRNewswire-FirstCall/--Abaxis,Inc.(Nasdaq: ABA...arebloodanalysissystems,announcedtodaythatClintSev...atthe21stAnnualPiperJaffrayHealthCareConferenceonW...illbeheldattheNewYorkPalaceHotelinNewYorkCity. ,...andmarketsportablebloodanalysissystemsforuseinanyv...

(Date:11/25/2009)...wswire-FirstCall/--NuVasive,Inc.(Nasdaq: NUVA ),am...inimallydisruptivesurgicaltreatmentsforthespine,an...November30,2009,at5:30p.m.ET/2:30p.m.PT.Theconfere...mentfortheCompany,sproductsandwillincludecommentsf...ion.Thedial-innumbersare1-877-407-4018fordomesticc...

(Date:11/25/2009)...swire/--Reportlinker.comannouncesthatanewmarketres...nasalDrugDelivery-USMarketTrends&Analysis htt...Delivery---US-Market-Trends--Analysis.html ,, ...ansionoftherapeuticapplicationsfromthedeliveryofco...emictherapeuticdrugs.Thefutureofthetechnologyhinge...

Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2 NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3 Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2 Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3 Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4 Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5 Sentry Data Systems Announces Claims Guardian 28TM 29 50150 1 Sentry Data Systems Announces Claims Guardian 28TM 29 50150 2 Sentry Data Systems Announces Claims Guardian 28TM 29 50150 3 Clavis Pharma Raises NOK 129 Million 28USD 20 Million 29 in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug 12798 1 Clavis Pharma Raises NOK 129 Million 28USD 20 Million 29 in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug 12798 2 Clavis Pharma Raises NOK 129 Million 28USD 20 Million 29 in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug 12798 3 Clavis Pharma Raises NOK 129 Million 28USD 20 Million 29 in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug 12798 4 Clavis Pharma Raises NOK 129 Million 28USD 20 Million 29 in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug 12798 5 Brown Takes Over Reins as Chair of AOSSM Medical Publishing Board of Trustees 50148 1 Brown Takes Over Reins as Chair of AOSSM Medical Publishing Board of Trustees 50148 2 Brown Takes Over Reins as Chair of AOSSM Medical Publishing Board of Trustees 50148 3

[0] Abaxis, Inc. to Present at the 21st Annual Piper Jaffray Health Care Conference [0] NuVasive Announces Conference Call and Webcast Regarding Reimbursement [0] Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis

...dy Comparing Leading Hepatitis C Therapies Provide...cal Practice, MILAN, Italy, April 26 Final resul..., clinical study comparing the,leading therapies f...e 43rd,Annual Meeting of the European Association ...tant insights that may help guide clinical practic...

...ts achieve undetectable HCV RNA levels following 4...egasys(R) plus Copegus(R) -, - Safety and tolerabi...ys plus Copegus - ...bsite -, - Conference call scheduled for Friday, A... and 7:00 PM CEST (Milan) -, PRINCETON, N.J. ...

Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C

Ultra-Sensitive Testosterone EIA

...kes it possible to determine the,vitamin levels in...es all reagents in,ready to use form for preparati... the columns. ,The advantage of HPLC analytics is ...ngle test. The HPLC complete,system enables even l...

Steroid 21-Hydroxylase (21-OH) Autoantibody RIA

...st kit is intended for the quantitative determinat...eptionally sensitive ELISA procedure offers sensit...iding for accurate establishment of post-ablation ...l methods. Furthermore, with the ability to accura...

Medicine Products:

Ultra-Sensitive Testosterone EIA Vitamin B6 (Pyridoxal-5-Phosphate) HPLC Assay Kit Steroid 21-Hydroxylase (21-OH) Autoantibody RIA KRONUS META-Tg ELISA test kit

Shamir Optical Industry Ltd. Reports Second Quarter 20...(ors research and development partners an...),Health